

Craig L Slingluff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5585101/publications.pdf>

Version: 2024-02-01

187
papers

9,086
citations

53794

45
h-index

51608

86
g-index

192
all docs

192
docs citations

192
times ranked

12911
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	28.9	1,515
2	Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma. <i>Cancer Research</i> , 2012, 72, 1070-1080.	0.9	461
3	Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells. <i>Journal of Clinical Oncology</i> , 2003, 21, 4016-4026.	1.6	303
4	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 943-955.	10.7	293
5	The Present and Future of Peptide Vaccines for Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 343-350.	2.0	248
6	Current status of granulocyte- macrophage colony-stimulating factor in the immunotherapy of melanoma. , 2014, 2, 11.		173
7	Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Muropeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial. <i>Clinical Cancer Research</i> , 2009, 15, 7036-7044.	7.0	157
8	Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. <i>Clinical Cancer Research</i> , 2001, 7, 3012-24.	7.0	155
9	Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. <i>Journal of Immunology</i> , 2018, 200, 432-442.	0.8	153
10	Terminal modifications inhibit proteolytic degradation of an immunogenic mart-127-35 peptide: Implications for peptide vaccines. <i>International Journal of Cancer</i> , 1999, 83, 326-334.	5.1	152
11	Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Muropeptide Vaccines for Melanoma in the Adjuvant Setting. <i>Clinical Cancer Research</i> , 2007, 13, 6386-6395.	7.0	149
12	Vaccines targeting helper T cells for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2017, 47, 85-92.	5.5	145
13	Immunologic and Clinical Outcomes of Vaccination With a Muropeptide Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule. <i>Journal of Clinical Oncology</i> , 2004, 22, 4474-4485.	1.6	141
14	CXC Chemokine Receptor 3 Expression by Activated CD8+ T cells Is Associated with Survival in Melanoma Patients with Stage III Disease. <i>Cancer Research</i> , 2004, 64, 7697-7701.	0.9	127
15	MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Muropeptide Vaccine for Melanoma. <i>Journal of Immunology</i> , 2005, 174, 3080-3086.	0.8	121
16	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. <i>International Journal of Cancer</i> , 2001, 92, 703-711.	5.1	114
17	Acral with melanoma: A review of 185 patients identification of prognostic variables. <i>Journal of Surgical Oncology</i> , 1990, 45, 91-98.	1.7	111
18	Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens. <i>Journal of Clinical Oncology</i> , 2008, 26, 4973-4980.	1.6	108

#	ARTICLE	IF	CITATIONS
19	Recommendations from the iSBTC-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. <i>Clinical Cancer Research</i> , 2011, 17, 3064-3076.	7.0	108
20	Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. <i>Journal of Translational Medicine</i> , 2005, 3, 39.	4.4	105
21	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. <i>OncoImmunology</i> , 2016, 5, e1235107.	4.6	104
22	Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multi-peptide Melanoma Vaccine. <i>Journal of Clinical Oncology</i> , 2011, 29, 2924-2932.	1.6	102
23	From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. , 2016, 4, 14.		101
24	A Multi-peptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer. <i>Journal of Immunotherapy</i> , 2008, 31, 420-430.	2.4	100
25	A Randomized Phase II Trial of Multi-peptide Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602). <i>Clinical Cancer Research</i> , 2013, 19, 4228-4238.	7.0	98
26	Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8 ⁺ T cells. <i>Science Immunology</i> , 2019, 4, .	11.9	95
27	Sequential Immune Escape and Shifting of T Cell Responses in a Long-Term Survivor of Melanoma. <i>Journal of Immunology</i> , 2005, 174, 6863-6871.	0.8	91
28	Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. , 2016, 4, 94.		91
29	Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens. <i>Cancer Immunology, Immunotherapy</i> , 2000, 48, 661-672.	4.2	89
30	Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. <i>Cell Reports</i> , 2021, 36, 109422.	6.4	89
31	Patient Preferences for Adjuvant Interferon Alfa-2b Treatment. <i>Journal of Clinical Oncology</i> , 2001, 19, 812-823.	1.6	85
32	Recent trends in National Institutes of Health funding for surgery: 2003 to 2013. <i>American Journal of Surgery</i> , 2015, 209, 1083-1089.	1.8	83
33	Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7440-7450.	7.0	74
34	CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1415-1425.	7.0	73
35	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. <i>Immunotherapy</i> , 2016, 8, 583-600.	2.0	71
36	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 921-937.	8.2	71

#	ARTICLE	IF	CITATIONS
37	Sentinel node biopsy in vulvar and vaginal melanoma: Presentation of six cases and a literature review. <i>Annals of Surgical Oncology</i> , 2002, 9, 840-846.	1.5	70
38	Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. <i>Journal of Translational Medicine</i> , 2011, 9, 26.	4.4	70
39	The annual risk of melanoma progression. Implications for the concept of cure. <i>Cancer</i> , 1992, 70, 1917-1927.	4.1	69
40	Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. <i>Journal of Hematology and Oncology</i> , 2017, 10, 152.	17.0	63
41	Amelanotic melanomas presenting as red skin lesions: a diagnostic challenge with potentially lethal consequences. <i>International Journal of Dermatology</i> , 2012, 51, 420-426.	1.0	61
42	A multi-peptide vaccine plus toll-like receptor agonists LPS or poly(I:CLC in combination with incomplete Freund's adjuvant in melanoma patients. , 2019, 7, 163.		59
43	Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 94-98.	1.3	57
44	Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2010, 33, 965-974.	2.4	56
45	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. <i>Oncolmmunology</i> , 2016, 5, e1240857.	4.6	56
46	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. <i>EBioMedicine</i> , 2016, 10, 85-100.	6.1	56
47	Immunity to Melanoma Antigens: From Self-Tolerance to Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 243-295.	2.2	55
48	Defective Human Leukocyte Antigen Class I-associated Antigen Presentation Caused by a Novel β 2-Microglobulin Loss-of-function in Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 18763-18773.	3.4	53
49	Progress and controversies in developing cancer vaccines. <i>Journal of Translational Medicine</i> , 2005, 3, 18.	4.4	49
50	A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. , 2017, 5, 92.		47
51	Clinical Activity and Safety of Combination Therapy with Temezirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). <i>Clinical Cancer Research</i> , 2013, 19, 3611-3620.	7.0	46
52	Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1149-1159.	4.2	44
53	MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. , 2020, 8, e000262.		44
54	Tumor antigens and tumor vaccines: Peptides as immunogens. , 1996, 12, 446-453.		40

#	ARTICLE	IF	CITATIONS
55	Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.. Journal of Clinical Oncology, 2014, 32, 9001-9001.	1.6	40
56	Melanoma vaccines. Current Opinion in Oncology, 2000, 12, 163-173.	2.4	39
57	Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma. , 2021, 9, e002273.		39
58	Autoimmune Toxicities Associated with the Administration of Antitumor Vaccines and Low-Dose Interleukin-2. Journal of Immunotherapy, 2005, 28, 412-419.	2.4	38
59	Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. Journal of Translational Medicine, 2010, 8, 79.	4.4	38
60	Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunology, Immunotherapy, 2016, 65, 1189-1199.	4.2	38
61	Vaccines, Adjuvants, and Dendritic Cell Activatorsâ€”Current Status and Future Challenges. Seminars in Oncology, 2015, 42, 549-561.	2.2	37
62	PRAME expression in 155 cases of metastatic melanoma. Journal of Cutaneous Pathology, 2021, 48, 479-485.	1.3	37
63	Use of selected reaction monitoring mass spectrometry for the detection of specific MHC class I peptide antigens on A3 supertype family members. Cancer Immunology, Immunotherapy, 2005, 54, 359-371.	4.2	36
64	T cells in the human metastatic melanoma microenvironment express siteâ€specific homing receptors and retention integrins. International Journal of Cancer, 2014, 134, 563-574.	5.1	36
65	Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunology, Immunotherapy, 2016, 65, 1201-1212.	4.2	36
66	Human Melanoma Cytolysis by Combined Inhibition of Mammalian Target of Rapamycin and Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor-2. Cancer Research, 2008, 68, 4392-4397.	0.9	35
67	Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Research, 2018, 28, 237-245.	1.2	35
68	Updates in adjuvant systemic therapy for melanoma. Journal of Surgical Oncology, 2019, 119, 222-231.	1.7	35
69	Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2. Cancer Immunology, Immunotherapy, 2009, 58, 867-876.	4.2	33
70	Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival. Clinical Cancer Research, 2015, 21, 3879-3887.	7.0	33
71	Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R. Melanoma Research, 2011, 21, 274-284.	1.2	32
72	The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides. Journal of Immunotherapy, 2012, 35, 78-88.	2.4	31

#	ARTICLE	IF	CITATIONS
73	Autologous lymph node cell-derived tumor-specific cytotoxic t-cells for use in adoptive immunotherapy of human melanoma. <i>Cancer</i> , 1988, 62, 84-91.	4.1	30
74	Peptide and Dendritic Cell Vaccines. <i>Clinical Cancer Research</i> , 2006, 12, 2342s-2345s.	7.0	30
75	A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 25-36.	4.2	30
76	Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 33-43.	4.2	30
77	MHC-Restricted Phosphopeptides from Insulin Receptor Substrate-2 and CDC25b Offer Broad-Based Immunotherapeutic Agents for Cancer. <i>Cancer Research</i> , 2014, 74, 6784-6795.	0.9	28
78	Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 779-786.	4.2	27
79	Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2728-2733.	1.5	27
80	Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. <i>Annals of Surgery</i> , 2015, 262, 456-464.	4.2	26
81	Peptide Vaccination in Montanide Adjuvant Induces and GM-CSF Increases CXCR3 and Cutaneous Lymphocyte Antigen Expression by Tumor Antigen-Specific CD8 T Cells. <i>Cancer Immunology Research</i> , 2013, 1, 332-339.	3.4	25
82	TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. <i>International Journal of Cancer</i> , 2015, 137, 1386-1396.	5.1	25
83	Extensive neurocristic hamartoma with skeletal muscle involvement. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 634-639.	1.3	24
84	VEGFR α 2 expression in human melanoma: Revised assessment. <i>International Journal of Cancer</i> , 2011, 129, 2807-2815.	5.1	24
85	Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 161-174.	4.2	24
86	Proliferating CD8+ T Cell Infiltrates Are Associated with Improved Survival in Glioblastoma. <i>Cells</i> , 2021, 10, 3378.	4.1	24
87	An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes. <i>Cancer Cell</i> , 2022, 40, 524-544.e5.	16.8	23
88	Immunogenicity for CD8+ and CD4+ T Cells of 2 Formulations of an Incomplete Freund's Adjuvant for Multipptide Melanoma Vaccines. <i>Journal of Immunotherapy</i> , 2010, 33, 630-638.	2.4	22
89	MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab. <i>Journal of Translational Medicine</i> , 2013, 11, 218.	4.4	22
90	The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?. <i>Melanoma Research</i> , 2017, 27, 211-217.	1.2	22

#	ARTICLE	IF	CITATIONS
91	Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines. <i>Annals of Surgical Oncology</i> , 2008, 15, 3538-3549.	1.5	21
92	A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. , 2014, 2, 23.		21
93	A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. <i>Contemporary Clinical Trials</i> , 2015, 41, 172-179.	1.8	21
94	Multi-peptide vaccines vialled as peptide mixtures can be stable reagents for use in peptide-based immune therapies. <i>Vaccine</i> , 2009, 27, 1764-1770.	3.8	20
95	Total body photography for skin cancer screening. <i>International Journal of Dermatology</i> , 2015, 54, 1250-1254.	1.0	20
96	Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. <i>JCO Precision Oncology</i> , 2021, 5, 589-601.	3.0	20
97	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
98	Melanoma-Specific Cytotoxic T Cells Generated from Peripheral Blood Lymphocytes. <i>Annals of Surgery</i> , 1989, 210, 194-202.	4.2	19
99	Pseudomonas Exotoxin-Mediated Delivery of Exogenous Antigens to MHC Class I and Class II Processing Pathways. <i>Cellular Immunology</i> , 2000, 203, 75-83.	3.0	18
100	Vaccine Strategy in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 337-351.	1.5	17
101	Bariatric surgery is independently associated with a decrease in the development of colorectal lesions. <i>Surgery</i> , 2019, 166, 322-326.	1.9	17
102	Skin Mapping With Punch Biopsies for Defining Margins in Melanoma: When You Don't Know How Far to Go. <i>Annals of Surgical Oncology</i> , 2008, 15, 3028-3035.	1.5	16
103	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
104	Competition Among Peptides in Melanoma Vaccines for Binding to MHC Molecules. <i>Journal of Immunotherapy</i> , 2004, 27, 425-431.	2.4	14
105	The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis. <i>Annals of Surgery</i> , 2019, 270, 712-722.	4.2	14
106	Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. <i>Cardio-Oncology</i> , 2020, 6, 21.	1.7	14
107	Peritoneal Cell-Free Tumor DNA as Biomarker for Peritoneal Surface Malignancies. <i>Annals of Surgical Oncology</i> , 2020, 27, 5065-5071.	1.5	14
108	Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). , 2021, 9, e000934.		14

#	ARTICLE	IF	CITATIONS
109	Evaluation of camera-based freehand SPECT in preoperative sentinel lymph node mapping for melanoma patients. <i>EJNMMI Research</i> , 2020, 10, 139.	2.5	14
110	Surgery investigators funded through the National Institutes of Health: A rebirth. <i>Surgery</i> , 2017, 161, 1482-1488.	1.9	13
111	Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1121-1132.	4.2	13
112	Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. , 2020, 8, e000544.		13
113	Assessment of the Toxicities of Systemic Low-Dose Interleukin-2 Administered in Conjunction with a Melanoma Peptide Vaccine. <i>Journal of Immunotherapy</i> , 2004, 27, 380-388.	2.4	11
114	Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 1095-1105.	4.2	11
115	Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. <i>Oncolmmunology</i> , 2016, 5, e1160193.	4.6	11
116	Academic or community practice? What is driving decision-making and career choices. <i>Surgery</i> , 2018, 164, 571-576.	1.9	11
117	Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4128-4128.	1.6	11
118	Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist. , 2021, 9, e002214.		11
119	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. <i>Oncolmmunology</i> , 2021, 10, 1898105.	4.6	11
120	Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials's experience. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1531-1539.	4.2	10
121	Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1490855.	4.6	10
122	<p>Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data</p>. <i>Breast Cancer: Targets and Therapy</i> , 2020, Volume 12, 69-75.	1.8	10
123	Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4125-4125.	1.6	10
124	Preventing the Spontaneous Modification of an HLA-A2-Restricted Peptide at an N-Terminal Glutamine or an Internal Cysteine Residue Enhances Peptide Antigenicity. <i>Journal of Immunotherapy</i> , 2004, 27, 177-183.	2.4	9
125	Interface of Signal Transduction Inhibition and Immunotherapy in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 360-366.	2.0	9
126	Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. <i>PLoS ONE</i> , 2015, 10, e0138210.	2.5	9

#	ARTICLE	IF	CITATIONS
127	Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells. <i>Cancer Immunology Research</i> , 2021, 9, 583-597.	3.4	9
128	Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates. <i>Journal of Translational Medicine</i> , 2021, 19, 371.	4.4	9
129	Vaccination for melanoma. <i>Current Oncology Reports</i> , 2000, 2, 292-299.	4.0	8
130	Surgical resection for bulky or recurrent axillary metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2012, 105, 21-25.	1.7	8
131	Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies. <i>Journal of Translational Medicine</i> , 2017, 15, 180.	4.4	8
132	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6995-7003.	1.5	8
133	Surgical Management of the Patient with Metastatic Melanoma to the Heart. <i>Journal of Cardiac Surgery</i> , 2013, 28, 124-128.	0.7	7
134	Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 3978-3984.	1.5	7
135	Building on the Promise of Cancer Vaccines for Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 529-531.	7.0	7
136	Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures. <i>Methods in Molecular Biology</i> , 2021, 2265, 573-587.	0.9	7
137	The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling. , 2022, 10, e003533.		7
138	Systems analysis of barrier molecule and ARNT-related gene expression regulation in melanoma. <i>Oncolmmunology</i> , 2019, 8, e1665978.	4.6	6
139	Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. <i>Scientific Reports</i> , 2020, 10, 18336.	3.3	6
140	Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2151-2164.	4.2	6
141	Myeloid Cell Infiltration Correlates With Prognosis in Cholangiocarcinoma and Varies Based on Tumor Location. <i>Journal of Immunotherapy</i> , 2021, 44, 254-263.	2.4	6
142	Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. , 2021, 9, e003272.		6
143	Final analysis of relapse-free survival in a multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine after resection of high-risk melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10017-10017.	1.6	6
144	IDO1 Expression in Melanoma Metastases Is Low and Associated With Improved Overall Survival. <i>American Journal of Surgical Pathology</i> , 2021, 45, 787-795.	3.7	6

#	ARTICLE	IF	CITATIONS
145	Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells. <i>Journal of Surgical Oncology</i> , 1990, 43, 67-72.	1.7	5
146	Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis. <i>Annals of Surgical Oncology</i> , 2019, 26, 3962-3971.	1.5	5
147	Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy. <i>Journal of Immunology</i> , 2021, 207, 333-343.	0.8	5
148	A pilot trial of vaccination with <sc>Carcinoembryonic antigen</sc> and Her2/neu peptides in advanced colorectal cancer. <i>International Journal of Cancer</i> , 2022, 150, 164-173.	5.1	5
149	Pilot trial of an Indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3033-3033.	1.6	5
150	Mismatch repair deficiency in cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 269-269.	1.6	5
151	Interleukin-2 Effects Deserve Further Study: A Need for Better Understanding of Biology and of Optimal Dose Regimens. <i>Journal of Clinical Oncology</i> , 2005, 23, 5267-5268.	1.6	4
152	Tailoring early-phase clinical trial design to address multiple research objectives. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 95-102.	4.2	4
153	Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. <i>Cancer Immunology Research</i> , 2021, 9, 1327-1341.	3.4	4
154	Salvage combination ipilimumab and nivolumab after failure of prior checkpoint inhibitor therapy in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21009-e21009.	1.6	4
155	Immune Mechanisms Orchestrate Tertiary Lymphoid Structures in Tumors Via Cancer-Associated Fibroblasts. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
156	Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. <i>Clinical Trials</i> , 2013, 10, 143-150.	1.6	3
157	Flexible Phase II Design for Partially Ordered Regimens with Application to Therapeutic Cancer Vaccines. <i>Statistics in Biosciences</i> , 2020, 12, 104-123.	1.2	3
158	Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry. <i>Methods in Enzymology</i> , 2020, 635, 81-93.	1.0	3
159	Phase 1/2 study of in situ vaccination with tremelimumab + intravenous (IV) durvalumab + poly-ICLC in patients with select relapsed, advanced cancers with measurable, biopsy-accessible tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3106-TPS3106.	1.6	3
160	Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFM): Implications for combination with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9559-9559.	1.6	3
161	Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 8972-8984.	1.8	3
162	Short length of stay and rapid recovery to normal function after surgery for metastatic melanoma to abdominal and retroperitoneal viscera. <i>Journal of Surgical Oncology</i> , 2009, 100, 481-483.	1.7	2

#	ARTICLE	IF	CITATIONS
163	A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1327-1334.	4.2	2
164	Phospho- β -catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. <i>Pathology Research and Practice</i> , 2021, 224, 153527.	2.3	2
165	Immunotyping and Quantification of Melanoma Tumor-Infiltrating Lymphocytes. <i>Methods in Molecular Biology</i> , 2021, 2265, 515-528.	0.9	2
166	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, e15171-e15171.	1.6	2
167	Peptide Vaccine: Overview. , 2017, , 427-439.		1
168	Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. , 2001, 92, 703.		1
169	A multi-peptide vaccine plus toll-like receptor agonists in melanoma patients, with evaluation of the vaccine site microenvironment and sentinel immunized node (Mel58; NCT01585350). <i>Journal of Clinical Oncology</i> , 2013, 31, TPS3125-TPS3125.	1.6	1
170	Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). <i>Journal of Clinical Oncology</i> , 2016, 34, 9517-9517.	1.6	1
171	A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3098-TPS3098.	1.6	1
172	Effect of gene expression profile (GEP) testing on clinical management in 19% of consecutively treated patients with stage IB/IIA melanoma at a single institution. <i>Journal of Clinical Oncology</i> , 2017, 35, e21080-e21080.	1.6	1
173	Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. <i>Journal of Surgical Oncology</i> , 2022, 125, 28-33.	1.7	1
174	Discussions About Clinical Trials Among Patients With Newly Diagnosed Lung and Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	0
175	Comparative Effectiveness of Lymphadenectomy Strategies During Curative Resection for Gastric Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2212-2218.	1.7	0
176	Childhood cancer survivors face markedly worse overall survival after diagnosis with breast cancer, melanoma, or colorectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 16-24.	1.7	0
177	Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis. <i>Journal of Clinical Oncology</i> , 2021, 39, 9576-9576.	1.6	0
178	Sentinel Node Assays. , 2005, , 434-444.		0
179	Immunology of Cancer. , 2008, , 1947-1963.		0
180	Evaluation of the safety and immunogenicity of intratumoral injection of interferon gamma (IFN γ) during vaccination in patients with subcutaneous or cutaneous metastases of melanoma (Mel51; Tj ETQq0 0 0 rgBTd/Overlock 10 Tf 00		0

#	ARTICLE	IF	CITATIONS
181	An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).. Journal of Clinical Oncology, 2013, 31, TPS3114-TPS3114.	1.6	0
182	Peptide Vaccine: Overview. , 2015, , 1-13.		0
183	Association of lung adenocarcinoma expression of Trop-2 protein with tumor infiltrating CD8 ⁺ T lymphocytes.. Journal of Clinical Oncology, 2015, 33, e18509-e18509.	1.6	0
184	Interim analysis of survival outcomes in a prospective cohort evaluating a prognostic 31-gene expression profile (GEP) test for melanoma.. Journal of Clinical Oncology, 2017, 35, 9573-9573.	1.6	0
185	Correlation of mesothelin expression and CD8 tumor infiltrating lymphocytes with prognosis in cholangiocarcinoma.. Journal of Clinical Oncology, 2017, 35, e15650-e15650.	1.6	0
186	Phase 1 study of NY-ESO-1 vaccine + ipilimumab (IPI) in patients with unresectable or metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, e15175-e15175.	1.6	0
187	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. Journal of the American Academy of Dermatology, 2022, , .	1.2	0